Granisetron

Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting BEMA Granisetron.

unknown title 2011

Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA "Triptan").

The Earth Times Online Newspaper 2010

Granisetron is the fourth product being launched under the partnership between Strides and Sagent Pharmaceuticals whereing Strides is developing and supplying more than 25 injectible products for the US market which will be marketed by Sagent.

News Centre@myiris.com India's Most Comprehensive Financial Destination 2010

According to 2009 IMS data, the US market for Granisetron hydrochloride injection approximated USD 26 million.

News Centre@myiris.com India's Most Comprehensive Financial Destination 2010

Granisetron hydrochloride injection will be made available in 0.1 mg per ml and 1.0 mg per ml single-dose vials and 4 mg per 4 ml multi-dose vials.

News Centre@myiris.com India's Most Comprehensive Financial Destination 2010

Granisetron hydrochloride injection is the generic equivalent of Kytril from F Hoffmann-La Roche AG.

News Centre@myiris.com India's Most Comprehensive Financial Destination 2010

Granisetron is currently marketed in oral and intravenous forms as the product Kytril.

National Business News - Local Business News | bizjournals 2010

Granisetron is a 5-HT3 receptor antagonist with well-established efficacy against chemotherapy-induced nausea and vomiting (CINV).

unknown title 2009

Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product.

THE MEDICAL NEWS 2009

Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product.

THE MEDICAL NEWS 2009